EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Mass., announced participation in two upcoming conferences. The Cowen 43rd Annual Healthcare Conference will feature a fireside chat on March 6, 2023, at 9:10 a.m. ET. The Guggenheim 4th Annual Healthy Altitudes Summit is scheduled for March 15, 2023, at 9:00 a.m. ET. Investors can access webcasts and archived replays via the company’s website. EyePoint specializes in developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery, including the investigational EYP-1901, currently in Phase 2 trials.

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

• Cowen 43^rd Annual Healthcare Conference
  Forum: Fireside Chat
  Date: Monday, March 6, 2023
  Time: 9:10 a.m. ET

• Guggenheim 4^th Annual Healthy Altitudes Summit
  Forum: Fireside Chat
  Date: Wednesday, March 15, 2023
  Time: 9:00 a.m. ET

A webcast and subsequent archived replay of each fireside chat, when available, may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:
Anne Marie Fields
Stern IR
Direct: 332-213-1956
annemarie.fields@sternir.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What are the upcoming conferences for EyePoint Pharmaceuticals (EYPT) in March 2023?

EyePoint Pharmaceuticals will present at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, and at the Guggenheim 4th Annual Healthy Altitudes Summit on March 15, 2023.

What time is EyePoint Pharmaceuticals (EYPT) presenting at the Cowen Conference?

The company will present at the Cowen Conference on March 6, 2023, at 9:10 a.m. ET.

When is EyePoint Pharmaceuticals (EYPT) participating in the Guggenheim Summit?

EyePoint Pharmaceuticals will participate in the Guggenheim Summit on March 15, 2023, at 9:00 a.m. ET.

How can I access the presentations from EyePoint Pharmaceuticals (EYPT)?

Webcasts and archived replays of EyePoint's presentations can be accessed through the Investors section of their website.

What is EYP-1901 and its status in EyePoint Pharmaceuticals' pipeline?

EYP-1901 is an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials.